Advertisement
Revenues for the three months ended September 30, 2007 totaled $1.654million, up 44.7 percent compared to revenues of $1.143 million in the thirdquarter of 2006.
Advertisement
The Company posted a gross profit of $2.384 million in the first ninemonths of 2007 and a gross profit of $994,449 in the third quarter. Thiscompares to 2006 nine-month gross profit of $527,070 and a third quarter grossprofit in 2006 of $250,104.
"The significant increase in revenue is partially due to the accretiveacquisitions Cord Blood America has made, which increased the number ofumbilical cord samples, and increased marketing efforts," said MatthewSchissler, CEO. "We are posting results that should be recognized assignificant achievements by the financial markets and by our investors."
One key point Mr. Schissler stressed is that the loss from operations forthe quarter ended September 30, 2007 is only $67, 082, down significantly from$672,239 for the three months ended June 30, 2007. "We said we want to runoperationally profitable. This number is the biggest key indicator that themanagement is committed to this goal," said Cord Blood America's CEO.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company ofCorCell, which facilitates umbilical cord blood stem cell preservation forexpectant parents and their children. Its mission is to be the most respectedstem cell preservation company in the industry. Collected through a safe andnon-invasive process, cord blood stem cells offer a powerful and potentiallylife-saving resource for treating a growing number of ailments, includingcancer, leukemia, blood, and immune disorders. To find out more about CordBlood America, Inc. (OTC Bulletin Board: CBAI), visit our website athttp://www.corcell.com. For investor information, visithttp://www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements,which are made pursuant to the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. We use words such as "anticipate,""believe," "expect," "future," "intend," "plan," and similar expressions toidentify forward-looking statements. These statements including those relatedto the growth of the industry, new stem cell treatments, and the Company'sperformance, are only predictions and are subject to certain risks,uncertainties and assumptions. Additional risks are identified and describedin the Company's public filings with the Securities and Exchange Commission.Statements made herein are as of the date of this press release and should notbe relied upon as of any subsequent date. The Company's past performance isnot necessarily indicative of its future performance. The Company does notundertake, and the Company specifically disclaims any obligation to update anyforward-looking statements to reflect occurrences, developments, events, orcircumstances after the date of such statement.CONTACT: Paul Knopick E & E Communications 949/707-5365 [email protected]
SOURCE Cord Blood America, Inc.
